Mike Hollan

A new report details the factors expected to drive the market’s growth in the coming years.

Several of Gleamer’s digital products will be incorporated into the ConcertAI platform.

The AR-focused company will present its platform on August 15, 2023.

The non-invasive device can be used to monitor the heart in a variety of ways.

A new report from Allied Market Research attributed multiple causes for the increase.

The devices will be available commercially in October 2023.

Hyfe’s CEO discusses the importance of quantifying one of the most common symptoms patients have: coughing.

Both companies will develop projects for an open-source web imaging platform.

Kindeva Drug Delivery will use the money to support its green inhaler production.

The imaging company signed deals with Prism Technologies Limited, Paragon Care, and Kral Medical Solutions.

The Magentiq-Colo can be used for real-time results during colonoscopies.

UltraSight says the technology allows for more widespread detection of heart disease.

A new trial will determine the effectiveness of using virtual reality to treat myopia in children. The treatment combines the use of a VR headset with a phone app that is designed to stimulate dopamine releases in the retina.

Shaman and Megill discuss Coirell’s new platform, GeneDose LIVE.

The center will research the use of new technologies to improve the diagnosis process.

Aside from robotics, modern ORs can benefit greatly by incorporating modern digital technologies.

Harhen discusses how new technologies are being used to reduce the failure rate of new drugs.

The treatment is for a major depressive disorder.

A new study suggests that the market could grow at a CAGR of just over 24% over the next four years.

The platform will utilize AI-powered software.

A panel at Medtech MVP 2023 discussed the benefits and difficulties of collecting and sharing data in the health industry.

The study, published in The Journal of Vascular Access, examined the performance of the device at Wilhelmina Children’s Hospital.

Grand View Research announced the projected growth for the market in a new report.

Motive Health Inc. announced the Motive Knee.

Dr. Davies is a pioneer of the instantaneous wave-free ratio (iFR) technique.

Cresilon, Inc., developed the gel that can control the bleeding from a wound without having to apply pressure.

The partnership includes BioNTX, Dallas College, and the DFW Hospital Council Foundation.

Eko Health developed the device, which has received 501(k) clearance from the FDA.

Dr. Yocca describes how BioXcel used AI to improve the drug development and re-innovation process.

Medical IP’s software analyzes bone, muscle, fat, organs, and the central nervous system.